Semaglutide, a medication originally developed for diabetes, has shown promising results in a recent clinical trial for weight loss and improved heart function in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. This groundbreaking study, published in the New England Journal of Medicine, offers new hope for this challenging patient population. Image: […]